01.20.15
Johnson & Johnson
4Q Revenues: $18.3 billion (-1%)
4Q Earnings: $2.5 billion (-29%)
FY Revenues: $74.3 billion (+4%)
FY Earnings: $16.3 billion (+18%)
Comments: Worldwide sales for the year were $74.3 billion, up 4%. Operational results increased 4% and the negative impact of currency was 4.5%. Domestic sales increased 7% while international sales decreased 7%. Worldwide Pharmaceutical sales were $32.3 billion for the year, up 15%, driven by new products and core products including: OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA (abiraterone acetate) for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA (canagliflozin) for type 2 diabetes; and IMBRUVICA (ibrutinib) for certain B-cell malignancies, or blood cancers. Additional core contributors to sales growth were STELARA, INVEGA SUSTENNA/XEPLION, SIMPONI/SIMPONI ARIA, and REMICADE. Worldwide Consumer sales were $14.5 billion, down 1%. Worldwide Medical Devices sales were $27.5 billion, down 3%. 4Q14 earnings included a charge of approximately $1.1 billion, primarily related to an increase in the litigation accrual, integration costs related to the acquisition of Synthes, Inc., and an in-process R&D charge.
4Q Revenues: $18.3 billion (-1%)
4Q Earnings: $2.5 billion (-29%)
FY Revenues: $74.3 billion (+4%)
FY Earnings: $16.3 billion (+18%)
Comments: Worldwide sales for the year were $74.3 billion, up 4%. Operational results increased 4% and the negative impact of currency was 4.5%. Domestic sales increased 7% while international sales decreased 7%. Worldwide Pharmaceutical sales were $32.3 billion for the year, up 15%, driven by new products and core products including: OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA (abiraterone acetate) for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA (canagliflozin) for type 2 diabetes; and IMBRUVICA (ibrutinib) for certain B-cell malignancies, or blood cancers. Additional core contributors to sales growth were STELARA, INVEGA SUSTENNA/XEPLION, SIMPONI/SIMPONI ARIA, and REMICADE. Worldwide Consumer sales were $14.5 billion, down 1%. Worldwide Medical Devices sales were $27.5 billion, down 3%. 4Q14 earnings included a charge of approximately $1.1 billion, primarily related to an increase in the litigation accrual, integration costs related to the acquisition of Synthes, Inc., and an in-process R&D charge.